A study testing whether a new weekly shot, tirzepatide, can help people drink less.
Recruiting now. Registry record last updated October 14, 2025.
- Who can join
- Adults 21 to 65, have alcohol use disorder, BMI 27+.
- What you take
- tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The study runs about 10 months.
- What you get
- Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
What this study is for
Primary condition: Alcohol Use Disorder. Also studied in: Obesity and Overweight, Alcohol.
Full scientific study title: Tirzepatide for Alcohol Use Disorder.
Who can join
Adults 21 to 65, have alcohol use disorder, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Meeting past-year DSM-5 criteria for AUD with at least moderate severity (≥ 4 symptoms)
- Average daily consumption of ≥40g (women) / ≥ 60 g (men) per day in the 28 days prior to baseline
- Body mass index ≥ 27kg/m2
- Willingness to attend weekly medication visits and complete all study procedures
- Ability to read and communicate in English
Key exclusion criteria
- Meeting past-year DSM-5 criteria for another substance use disorder (except tobacco use disorder or mild cannabis use disorder)
- Recent (past 30 day) self-report of illicit drug use (excluding cannabis) or non-prescribed opioids; or positive urine screen for illicit drugs. A positive screen for opioids will be allowed if the participant is prescribed an opioid replacement therapy medication and can provide documentation.
- History of significant alcohol withdrawal, as indicated by history of seizure, delirium tremens; history of hospitalization for withdrawal-related symptoms; a CIWA score \>9 at assessment; or a baseline score 4+ on the Prediction of Alcohol Withdrawal Severity (PAWS) scale.
- Recent (past 3 months) engagement in behavioral or pharmacological alcohol use treatment or currently mandated to receive treatment
- History of chronic or acute pancreatitis
Where this trial is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
California1 site
- Keck School of Medicine, University of Southern CaliforniaLos Angeles, California
Timeline
Started enrolling: October 6, 2025. Expected completion: August 31, 2026. Last updated on ClinicalTrials.gov: October 14, 2025.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
